ArticleCureus2026
Diagnostic Performance of Triglyceride-Glucose Body Mass Index (TyG-BMI), Fibrosis-4 Index (FIB-4), and Their Combined Model for Clinically Significant Liver Fibrosis in Type 2 Diabetes Mellitus.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction Patients with type 2 diabetes mellitus are at increased risk of clinically significant liver fibrosis, while commonly used noninvasive fibrosis scores do not perform equally well in all patients. The triglyceride-glucose body mass index (TyG-BMI) captures metabolic changes and excess body weight and may add information not included in the fibrosis-4 index (FIB-4). This study assessed how well the TyG-BMI and FIB-4 identified clinically significant liver fibrosis when used alone and together. Methods This cross-sectional diagnostic accuracy study included 280 patients with type 2 diabetes mellitus. The TyG-BMI and FIB-4 were calculated using the patients' clinical and laboratory measurements. Transient elastography served as the reference test, with liver stiffness measurement ≥8 kPa used to identify clinically significant fibrosis. Accuracy was assessed by receiver operating characteristic analysis and by calculating sensitivity, specificity, positive predictive value, negative predictive value, and overall accuracy. Results Clinically significant liver fibrosis was present in 66 of 280 patients (23.6%). The TyG-BMI showed moderate discrimination, with an area under the curve (AUC) of 0.710 (95% CI 0.633-0.783), while the FIB-4 showed an AUC of 0.801 (95% CI 0.736-0.857). At a FIB-4 cutoff of 1.30, sensitivity was 78.8%, specificity was 69.2%, and negative predictive value was 91.4%. The combined TyG-BMI-FIB-4 model achieved an AUC of 0.850 (95% CI 0.796-0.901), with 78.8% sensitivity, 79.0% specificity, 53.6% positive predictive value, 92.3% negative predictive value, and 78.9% accuracy. The internally validated AUC was 0.845. Conclusions Combining the TyG-BMI with the FIB-4 improved discrimination for transient elastography-defined clinically significant liver fibrosis compared with either index alone. This approach may improve noninvasive fibrosis risk stratification in patients with type 2 diabetes mellitus, but external validation is required before clinical application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.